Skip to content

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07566975
Enrollment
50
Registered
2026-05-05
Start date
2026-03-31
Completion date
2026-11-30
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

Neurotrophic Keratitis, Dry Eye

Brief summary

patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye

Interventions

one drop in both eyes twice a day

Sponsors

Neuro-Ophthalmology of Texas
Lead SponsorOTHER
Harrow Inc
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires

Exclusion criteria

* Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring / zero sensitivity

Design outcomes

Primary

MeasureTime frameDescription
Corneal fluorescein stainingBaseline compared to week 4pre vs post treatment

Countries

United States

Contacts

CONTACTLaura Perez
lperez@neuroeye.com12817238593
CONTACTRosa A Tang, MD
lperez@neuroeye.com713-258-0009
PRINCIPAL_INVESTIGATORRosa A. Tang

Neuro Ophthalmology of TX

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026